Who Paid My Doc
Ananth Shankar
Nuclear Cardiology Bronx, NY Medical Doctor
NPI 1811153695 CMS profile 127791
2015 Grand Concourse, Bronx, NY 10453
General payments
$969
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$5,625
Through program year 2025, Ananth Shankar of Bronx, NY is reported in the CMS Open Payments database as having received $969 across 17 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $5,625 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 38th percentile of Nuclear Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $98 | 1 | |
| 2024 | General | $67 | 1 | |
| 2023 | General | $431 | 5 | |
| 2022 | General | $111 | 1 | |
| 2020 | General | $18 | 1 | |
| 2019 | General | $244 | 8 |
Beside peers
- Ananth Shankar
- Nuclear Cardiology median
- Middle half of Nuclear Cardiology
- National median
In program year 2025, general payments to Ananth Shankar were reported at $98. Among 99 Nuclear Cardiology profiles paid that year, the median was $434 and the middle half received between $138 and $985.
Show as a table
| Year | Ananth Shankar | Nuclear Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $244 | $552 | $91–$1,768 | $163 |
| 2020 | $18 | $204 | $61–$1,106 | $114 |
| 2021 | $0 | $354 | $99–$886 | $132 |
| 2022 | $111 | $506 | $101–$1,186 | $149 |
| 2023 | $431 | $545 | $148–$1,432 | $160 |
| 2024 | $67 | $484 | $131–$1,430 | $164 |
| 2025 | $98 | $434 | $138–$985 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 12 drugsPart D claims
290
Drug cost
$22,901
Branded share of claims
15.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xarelto Rivaroxaban | Brand | 20 | $20,252 | |
| Atorvastatin Calcium | Generic | 49 | $493 | |
| Metoprolol Succinate | Generic | 27 | $481 | |
| Losartan Potassium | Generic | 33 | $375 | |
| Amlodipine Besylate | Generic | 45 | $373 | |
| Rosuvastatin Calcium | Generic | 17 | $316 | |
| Omeprazole | Generic | 20 | $164 | |
| Metformin Hcl | Generic | 18 | $162 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 24 | $131 | |
| Simvastatin | Generic | 12 | $77 |
The 10 drugs with the highest cost, of 12 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 45 billing codesPaid by Medicare
$532,309
Medicare patients
1,329
Services billed
5,732
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Diabetes | 75% | |
| High blood pressure | 75% | |
| Arthritis | 70% | |
| Chronic kidney disease | 42% | |
| Alzheimer's or dementia | 40% | |
| Heart failure | 38% | |
| Ischemic heart disease | 38% | |
| Depression | 37% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, regadenoson, 0.1 mg J2785 | Office | 81 | 310 | $1,573 |
| Injection, dipyridamole, per 10 mg J1245 | Office | 32 | 38 | $113 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
17 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nuclear Cardiology in New York
Related records
Nuclear Cardiology in New York
Practitioners in the same specialty and state, ranked by reported value.
All Nuclear Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.